The impact of targeted therapies on molecular alterations identified by an institutional molecular tumor board: an approach based on ESCAT classification

Autor: Rahmani Narj Abadi, K., Dupain, C., Guillou, I., Sanchez, R., Nedara, K., Marret, G., Hescot, S., Sablin, M-P., Castel-Ajgal, Z., Neuzillet, C., Borcoman, E., Bello Roufai, D., Rodrigues, M., Asnacios Lecerf, A., Callens, C., Trabelsi-Grati, O., Melaabi, S., Driouch, K., Antonio, S., Lemaitre, E., Nijnikoff, M., Vincent Salomon, A., Allory, Y., Cyrta, J., Ghazelian, H., Girard, E., Servant, N., Stoppa-Lyonnet, D., Wong, J., Hamza, A., Masliah-Planchon, J., Kamal, M., Bièche, I., Le Tourneau, C.

Publikováno v: In ESMO Real World Data and Digital Oncology December 2024 6

LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1

Autor: Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., Sorensen, R., Forster, A., Fraser, P., Cohen, J. I., Alexander, I., Wintergerst, U., Frebourg, T., Aurias, A., Stoppa-Lyonnet, D., Romana, S., Radford-Weiss, I., Gross, F., Valensi, F., Delabesse, E., Macintyre, E., Sigaux, F., Soulier, J., Leiva, L. E., Wissler, M., Prinz, C., Rabbitts, T. H., Le Deist, F., Fischer, A., Cavazzana-Calvo, M.

Publikováno v: Science, 2003 Oct . 302(5644), 415-419.

Externí odkaz: https://www.jstor.org/stable/3835321

Genetic clinicians' confidence in BOADICEA comprehensive breast cancer risk estimates and counselees' psychosocial outcomes: A prospective study

Autor: Bredart, A., Pauw, A. de, Tuchler, A., Lakeman, I.M.M., Anota, A., Rhiem, K., Schmutzler, R., Asperen, C.J. van, Devilee, P., Stoppa-Lyonnet, D., Kop, J.L., Dolbeault, S.

Publikováno v: Clinical Genetics
Clinical Genetics, Wiley, 2022, pp.1-10. ⟨10.1111/cge.14147⟩
Clinical Genetics, 2022, pp.1-10. ⟨10.1111/cge.14147⟩
Clinical Genetics, 102(1), 30-39. WILEY

International audience; Counseling for familial breast cancer focuses on communicating the gene test result (GENE) to counselees, but risk prediction models have become more complex by including non-genetic risk factors (NGRF) and polygenic risk scor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1a58eab10675a059e25f3eb54409349
https://doi.org/10.1111/cge.14147

38MO Validation study of the ShallowHRDv2 assay for homologous recombination deficiency (HRD) detection in high-grade ovarian carcinomas (HGOC) in the first-line setting, from the phase III PAOLA-1/ENGOT-ov25 trial

Autor: Callens, C., Rodrigues, M.J., Briaux, A., Browaeys, E., Eeckhoutte, A., Pujade-Lauraine, E., Renault, V., Stoppa-Lyonnet, D., Bieche, I., Bataillon, G., Heitz, F., Chiara-Cecere, S., Rubio Perez, M.J., Berger, R., Jakobi Nøttrup, T., Colombo, N., Vergote, I.B., Ray-Coquard, I.L., Stern, M-H., Popova, T.

Publikováno v: In ESMO Open February 2023 8(1) Supplement 1

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.